Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases

被引:10
作者
Nieder, Carsten [1 ,2 ]
Haukland, Ellinor [1 ]
Pawinski, Adam [1 ]
Dalhaug, Astrid [1 ]
机构
[1] Nordland Hosp, Dept Oncol & Palliat Med, Bodo, Norway
[2] Univ Tromso, Fac Hlth Sci, Inst Clin Med, Tromso, Norway
来源
BMC UROLOGY | 2010年 / 10卷
关键词
SKELETAL COMPLICATIONS; MEN; CARCINOMA; SURVIVAL;
D O I
10.1186/1471-2490-10-23
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: The purpose of this study was to determine the risk factors for and incidence as well as prognostic impact of pathologic fracture (PF) and metastatic spinal cord compression (MSCC) in patients with bone metastases (BM) from prostate cancer. Methods: Retrospective cohort study including 61 consecutive patients seen at Nordland hospital's department of oncology between 2007 and 2009. The initial diagnosis of BM might have been made earlier. Twenty-nine patients (48%) received taxotere and 72% zoledronic acid after diagnosis of BM. Results: Median actuarial survival after diagnosis of BM was 23 months. Six patients (10%) were alive at 5 years. Bone pain at baseline was present in 49% of patients. Eighty-nine percent required external beam radiotherapy and/or radioisotopes after diagnosis of BM. Seventeen patients (28%) developed at least one major skeletal complication, i.e. MSCC or PF (4 of them developed more than one). The actuarial risk was 44% at 4 and 5 years. Most events developed before treatment with zoledronic acid and/or taxotere. Median survival from diagnosis of either MSCC or PF was 11 months (5 months from MSCC). We did not identify statistically significant risk factors for development of major skeletal complications. Serum alkaline phosphatase above median value and age less than or equal to 70 years were the only risk factors approaching significance. Conclusions: We found high rates of major skeletal complications in this unselected contemporary group of patients. Identification of risk factors might guide the development of early interventions aiming at prevention of MSCC and PF.
引用
收藏
页数:6
相关论文
共 20 条
  • [1] Pre- and post-treatment daily life function in patients with hormone resistant prostate carcinoma treated with radiotherapy for spinal cord compression
    Aass, N
    Fosså, SD
    [J]. RADIOTHERAPY AND ONCOLOGY, 2005, 74 (03) : 259 - 265
  • [2] Bayley A, 2001, CANCER, V92, P303, DOI 10.1002/1097-0142(20010715)92:2<303::AID-CNCR1323>3.0.CO
  • [3] 2-F
  • [4] Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease
    Berruti, A
    Tucci, M
    Mosca, A
    Tarabuzzi, R
    Gorzegno, G
    Terrone, C
    Vana, F
    Lamanna, G
    Tampellini, M
    Porpiglia, F
    Angeli, A
    Scarpa, RM
    Dogliotti, L
    [J]. BRITISH JOURNAL OF CANCER, 2005, 93 (06) : 633 - 638
  • [5] *CANC REG NORW, 2008, CANC NORW 2007 CANC
  • [6] Metastatic prostate carcinoma to bone - Clinical and pathologic features associated with cancer-specific survival
    Cheville, JC
    Tindall, D
    Boelter, C
    Jenkins, R
    Lohse, CM
    Pankratz, VS
    Sebo, TJ
    Davis, B
    Blute, ML
    [J]. CANCER, 2002, 95 (05) : 1028 - 1036
  • [7] Clinical features of metastatic bone disease and risk of skeletal morbidity
    Coleman, Robert E.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6243S - 6249S
  • [8] Genant HK, 1997, J RHEUMATOL, V24, P1212
  • [9] VERTEBRAL FRACTURE ASSESSMENT USING A SEMIQUANTITATIVE TECHNIQUE
    GENANT, HK
    WU, CY
    VANKUIJK, C
    NEVITT, MC
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1993, 8 (09) : 1137 - 1148
  • [10] Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy
    Greenspan, Susan L.
    Nelson, Joel B.
    Trump, Donald L.
    Wagner, Julie M.
    Miller, Megan E.
    Perera, Subashan
    Resnick, Neil M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) : 4426 - 4434